僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Amivantamab （JNJ-61186372） is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells